It has been unclear whether a graft-versus-leukemia (GVL) effect assists in the control of juvenile myelomonocytic leukemia (JMML) following allogeneic bone marrow transplant. We describe a patient with JMML who relapsed early after an unrelated donor transplant, and following withdrawal of immunosuppression developed graft-versus-host disease (GVHD). Associated with GVHD the proportion of donor cells measured by variable nucleotide tandem repeat (VNTR) analysis increased, and peripheral blasts and cutaneous disease were eliminated. These findings strongly suggest that GVL has a role in the control of JMML. Keywords: JMML; JCML; GVL; GVHD; donor lymphocytes Allogeneic bone marrow transplantation (BMT), including unrelated donor BMT, has become standard therapy for many high risk or relapsed leukemias.
thrombocytopenia and high fetal hemoglobin concentrations, but marrow blast counts are typically lower than observed with acute leukemia. 5, 6 The long-term disease-free survival of patients with JMML treated with intensive chemotherapy is inferior to allogeneic BMT, [5] [6] [7] although a large number of patients continue to relapse following transplant. [7] [8] [9] [10] Due to the high rate of JMML relapse, it has been postulated that unrelated donor (URD) BMT may be an important treatment modality, as it is associated with a decreased rate of relapse in patients with CML. 1, 11 However, it has been unclear if there is a significant GVL effect directed against JMML. We present a patient who relapsed early following URD BMT for JMML who achieved remission following withdrawal of immunosuppressive therapy and subsequent development of GVHD, providing evidence of a GVL effect for JMML.
Case report
A 4-year-old girl presented at 3 years of age with hepatosplenomegaly, a maculopapular rash and thrombocytopenia. Mild anemia was noted, with a normal white blood cell count but 15% circulating blasts. Examination of the bone marrow was significant for erythroid hyperplasia with 5% myeloblasts; cytogenetics revealed a normal karyotype. The cutaneous lesions were biopsied and were consistent with a leukemic infiltrate. The fetal hemoglobin level was 73%. These findings were consistent with a diagnosis of JMML, and the patient was treated with cis-retinoic acid (3 mg/kg/daily) as well as cytosine arabinoside (75 mg/m 2 four times weekly). This regimen led to resolution of skin disease and served to decrease the degree of hepatosplenomegaly. As no HLA-matched sibling was available to serve as BMT donor, an unrelated donor search was initiated, and a suitable donor (A, B matched, DR␤1 mismatch) was identified. During a pre-transplant evaluation 4 months after the initial diagnosis, she again developed massive hepatosplenomegaly and skin disease and was treated with 'DCTER' therapy (dexamethasone, cytarabine, 6-thioguanine, etoposide, daunorubicin), 12 which led to a decrease in her organomegaly and skin lesions. Prior to her transplant she was shown to have 6% blasts on a marrow evaluation, and had moderate hepatosplenomegaly.
The transplant preparative regimen consisted of cyclo-phosphamide (120 mg/m 2 ) and total body irradiation (1320 rad), with methotrexate and cyclosporin A (CsA) as graftversus-host disease (GVHD) prophylaxis. The patient was transplanted with an unmanipulated graft, and achieved an ANC of 5 × 10 8 cells/l on day 28, and a bone marrow evaluation on day 21 revealed 100% donor cell engraftment as determined by a polymerase chain reaction-based amplification of variable nucleotide tandem repeat markers (VNTR). Evaluation of the marrow showed an orderly maturation of erythroid precursors. She developed grade II skin GVHD, and on day 58 following BMT was begun on prednisone (60 mg/m 2 /day), with a brisk response. On day 69 she was noted to have circulating blasts, increasing to 28% of her white cells within 10 days. In addition, a rash identical in appearance to her previous cutaneous leukemia was observed. Bone marrow evaluation was consistent with recurrence of her disease, with 97% of cells of erythroid origin despite a low blast count (19.5% proerythroblasts). In addition, there was a marked shift to the left, with basophilic normoblasts observed. Marrow analysis by VNTR documented 32% of nucleated marrow cells to be of donor origin. CsA was withdrawn abruptly, and steroids tapered over 7 days in an attempt to induce GVHD and possibly a graft-versus-leukemia (GVL) effect. She developed generalized and marked erythroderma, and on day 82 steroids were restarted. She had also developed evidence of gastrointestinal and liver GVHD, with a maximum total bilirubin of 18.5 mg/dl on day 100. During this time, due to the difficulty in monitoring her disease status quantitatively with bone marrow evaluations, high sensitivity VNTR analysis on peripheral blood was performed weekly (Figure 1 ). These determinations revealed a progressive increase in the proportions of donor cells in the marrow donor cells from 32% (day 69) to 48% (day 86) and finally to 100% (day 110). Her skin GVHD improved and she was weaned off steroids, despite moderate hyperbilirubinemia. She currently remains 100% engrafted by VNTR analysis 14 months following BMT, with mild chronic skin GVH and no evidence of leukemia. When relapse was identified (week 10) cyclosporin A was discontinued and GVHD developed, with an associated increase in the proportion of donor DNA in both blood and marrow.
Methods of analysis
Samples of peripheral blood from the donor and recipient were obtained prior to BMT and were analyzed using a series of anonymous genetic markers to identify the most informative alleles; the minisatellite D1S80 was selected for this donor/recipient pair. Chimerism testing was performed based on amplification of the minisatellite DNA sequences D1S80 using the polymerase chain reaction (PCR). 13 Conditions for the PCR reactions had been previously optimized so as to be reliably quantitative and eliminate the effect of differential amplification of smaller over larger sized alleles. Analysis of the DNA products was performed by automated fluorescent detection at 630 nm, 14 using an ABI 373 DNA sequencer (Applied Biosystem, Foster City, CA, USA). The resulting chromogram was processed with GenScan and Genotyper software. Calculation of percent engraftment was based on the ratio of the area under the curve for the donor-specific alleles divided by the sum of the areas under the curve of all detected alleles (recipient and donor), which for this marker is represented by the ratio (D1+C/D1+C+R1) × 100. 15 Each sample tested was routinely compared to products of D1S80 PCR including a negative control consisting of a reaction solution with no added DNA template, and two separate sensitivity controls, comprised of DNA from two admixed cell lines at 95:5 and 99:1 proportions. The calculated percent engraftment for each of the subjects samples was identical when a second minisatellite, Apo B, was used.
Discussion
Allogeneic bone marrow transplantation is the most effective therapy in the treatment of JMML; 16, 17 however, relapse remains a primary reason for treatment failures with JMML. The role of GVL in the control of JMML relapse has been unclear. We present evidence that GVL can reverse early relapse of JMML following allogeneic BMT associated with withdrawal of immunosuppression and subsequent development of GVHD. Initial (day 21) 100% donor engraftment was followed by the emergence of circulating leukemic blasts and progressive loss of donor cells while on prednisone and CsA, as evidenced by a decrease in donor DNA to approximately 30% donor cells by PCRbased VNTR analysis. Within a week of withdrawal of steroids and CsA, skin and hepatic GVHD developed, and subsequent marrow and peripheral blood VNTR testing documented increasing proportions of donor cell DNA. By 6 weeks following withdrawal of immunosuppression, the patient had achieved remission by VNTR which has persisted to 14 months post BMT.
There have been several reports suggestive of a GVL effect in JMML. Lutz et al 7 described a patient who relapsed after BMT, and was treated with withdrawal of CsA as well as 6-mercaptopurine, and achieved a sustained remission. 7 Rassam et al 10 reported a patient with JMML who on the initial (day 26) evaluation after BMT was shown to have approximately 30% cells of donor origin. This patient had also received CsA GVHD prophylaxis, and following withdrawal developed GVHD and eventually achieved 100% donor status. While these reports document changes in engraftment status in patients with JMML and disease-free survival, we describe evidence of rapid progression of our patient's leukemia based on the presence of circulating blasts and evidence of marrow relapse in a situation where 100% donor cells was demonstrated on day 21. The clearing of blasts from the blood, normalization of the marrow and increased proportion of donor-derived DNA following the onset of GVHD without chemotherapeutic agents provides evidence of the ability of the GVL response to control JMML. The routine availability of high sensitivity PCR-based DNA engraftment studies using the technique described greatly simplified the monitoring of donor chimerism, which appeared to correlate clinically with the status of the patient's disease. This proved especially helpful in this patient with JMML, as the morphologic evaluation of the marrow was less informative quantitatively for the presence of disease in this patient.
In summary, allogeneic BMT is the only therapeutic regimen that has been shown to be curative for patients with JMML. While relapse has been very high following BMT, our data provide evidence that GVL has an active role in the control of JMML. This may prove important in the design of GVHD prophylaxis regimens following allogeneic BMT, and suggests that aggressive treatment of GVHD may increase the likelihood of relapse. In addition, immunotherapy including infusions of donor-derived lymphocytes may also prove useful in patients who relapse after BMT.
